BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines external Cost of Development Programs ($M) ($M)
Form 10-Q / 10-K MD&A R&D Expense Summary Table
Latest, FY2025
754
Period ended Dec 31, 2025
Change on a year earlier
+39.7%
539 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External Cost of Development Programs ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 754 | +39.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 539 | -2.2% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 551 | +17.4% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 469 | -1.7% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 478 | -4.9% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 502 | – | Form 10-K (filed 2022-02-28) ↗ |
Breakdown
What makes up external cost of development programs ($m)
- External R&D — BRUKINSA (zanubrutinib, BTKi) ($M)97.6 · FY2025
- External R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M)56.2 · FY2025
- External R&D — BEQALZI / Sonrotoclax (BGB-11417, BCL2 Inhibitor) ($M)177 · FY2025
- External R&D — Tacabrutideg (BGB-16673, BTK CDAC) ($M)93.8 · FY2025
- External R&D — BGB-43395 (CDK4 Inhibitor) ($M)18.0 · FY2025
- External R&D — PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY17–FY23)8.96 · FY2023
- External R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23)77.7 · FY2023
- External R&D — BGB-A445 (Anti-OX40 Agonist) ($M, FY20–FY23)15.8 · FY2023
- External R&D — Other Internal Clinical & Preclinical Projects ($M)312 · FY2025
- External R&D — R&D Collaboration Projects ($M)105 · FY2025
Cite this data
StockData. (2026). BeOne Medicines External Cost of Development Programs ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_ext_dev_programs
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.